Clinical Presentation of Methamphetamine Withdrawal
Methamphetamine withdrawal presents as a biphasic syndrome characterized by an acute phase (7-10 days) dominated by hypersomnia, hyperphagia, dysphoric mood, and depression, followed by a subacute phase (2+ weeks) with persistent low-level symptoms including craving, sleep disturbances, and residual psychiatric symptoms. 1, 2
Acute Withdrawal Phase (First 7-10 Days)
The acute phase begins within 24 hours of last use and peaks early, then declines linearly over the first week 2:
Core Symptoms
- Dysphoric mood and depression - the most prominent feature, ranging from mild-moderate to severe at onset, largely resolving within the first week 1, 3
- Hypersomnia - markedly increased sleeping that persists throughout acute withdrawal 1, 2
- Hyperphagia - increased appetite and eating 1, 2
- Fatigue - profound exhaustion that improves gradually 1, 4
Associated Symptoms
- Psychomotor changes - either retardation or agitation 1
- Anxiety symptoms - present but less severe than depressive symptoms 2, 3
- Vivid, unpleasant dreams 1
- Psychotic symptoms - may be present initially in those with heavy use, but typically resolve within 1 week 3
Subacute Withdrawal Phase (Weeks 2-5+)
Following acute withdrawal, symptoms stabilize at lower levels but persist 2, 5:
Persistent Features
- Craving - does not significantly decrease until the second week, then continues at reduced levels through at least week 5 3
- Sleep disturbances - disrupted sleep quality and unrefreshed sleep persist beyond 4 weeks, even as other symptoms resolve 6
- Residual psychiatric symptoms - associated with potential neurotoxicity, may last several months 5
Important Clinical Considerations
Symptom Severity Factors
- Frequency of use - more frequent methamphetamine use correlates with more severe withdrawal 4
- Gender differences - females report more frequent withdrawal symptoms when present 4
- Pain severity - approximately 20% report withdrawal as "very or extremely painful" 4
Common Pitfalls
The FDA label emphasizes that withdrawal occurs "after abrupt discontinuation or significant dose reduction following prolonged use" 1. Clinicians should not mistake the resolution of acute depressive and psychotic symptoms within the first week as complete recovery, since craving and sleep disturbances persist much longer 3, 6. This extended subacute phase represents a critical period for relapse risk 3.
Cardiovascular Monitoring
Unlike some substance withdrawals, methamphetamine withdrawal does not produce clinically significant alterations in blood pressure or heart rate 6. The primary concerns are psychiatric and sleep-related rather than cardiovascular.